期刊文献+

连续流反应技术开发及其在制药危险工艺中的应用 被引量:5

Development and Application of Continuous-flow Technology in Pharmaceutical “Hazardous Processes”
原文传递
导出
摘要 当前,化学制药过程仍然存在许多极易导致泄漏、火灾、爆炸、中毒的工艺——"危险工艺"。传统间歇釜式生产方式存在传质传热效率低、产品质量稳定性差、生产效率低等缺点,尤其在处理"危险工艺"过程中,釜式反应过程安全隐患大。而连续流反应技术具有在线反应量少、传质传热效率高、参数控制精确、工艺稳定、安全高效等优点,能使"危险工艺"在安全高效的可控模式下运行。本文主要介绍连续流反应技术在光气及光气化、氯化、硝化等典型"危险工艺"中的成功应用案例,进一步阐明连续流反应技术的显著优点。 Currently, there are many processes in pharmaceutical industry, namely "hazardous processes",which may be easy to leak, highly flammable, or involved in explosive or toxic chemicals. Batch processes often facesome problems like low mass/heat transfer efficiency, lack of stability, low productivity, etc. Especially for "hazardous processes", batch reactors have some serious safety issues. Continuous-flow technology, in the other hand, has some advantages such as high mass/heat transfer efficiency, the precise control of reaction parameters, intrinsic safety, high productivity and equality, which make "hazardous processes" to be conducted under safe and efficient procedures.This article mainly int-roduced some applications of continuous-flow technology in typical "hazardous processes" like phosgenation, chlorination, nitration, etc.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2017年第4期469-482,共14页 Chinese Journal of Pharmaceuticals
关键词 连续流 危险工艺 过程强化 安全 continuous-flow hazardous processes process intensification safety
  • 相关文献

参考文献3

二级参考文献127

  • 1汪宝和,颜范勇,井欣,张德立,马海洪.二甲苯砜加入法抑制甲苯磺化副反应[J].石油化工,2004,33(9):857-860. 被引量:4
  • 2颜范勇,汪宝和,井欣,张德立,刘邦孚.三氧化硫磺化甲苯反应的工艺条件研究[J].化学反应工程与工艺,2005,21(4):370-374. 被引量:6
  • 3Wang Q, Strab R, Kardos P, et al. Application and limitation of inhibitors in drug-transporter interactions studies [ J ]. International Journal of Pharmaceutics, 2008, (356) :12 - 18.
  • 4Care~ller E, Salas J, Merlos M, etal. Novel azo de- rivatives as prodrugs of 5-aminosalicyllc acid and ami- no derivatives with potent platelet activating faltor an- tagonlse activity[J]. J Med Chem,2001,44: 3001 - 3013.
  • 5Carta F, Maresca A, Scozzafava A, et al. Carbonic anhydraset inhibitors [ J ]. Bioorg Meal Chem,2009,17 : 7093 - 7099.
  • 6Zaber H, Khan A A, Palandm J, et al. Breast cancer resistance protein 15 a major determinant of surfasala- zine absorption and elimination in the mouse[J]. Mo- lecular Pharmaceutics ,2005,3:55 - 61.
  • 7Juneka R. Antileukotrienlc N-arylethyl-2-arylacetamides in the treatment of tdcerative colitis [ J ]. European Journal of Medicinal Chemistry, 2007, 42:1084 - 1094.
  • 8Novacck A, Sedlackova V, Komer J, et al. Method of producing sulfasalazine[P]. CS 273 928,1992.
  • 9Ekmuribe N N, Malson E. 5-ASA derivatives[ P]. WO 2 002 018 330,2002.
  • 10Habens F, Srinivasan N, Oaldey F, et al. Novel sur- fasalazine analogues with enhanced NF-KB inhibitory and apolosis promoting activity [ J ]. Apoptosis, 2005, 10:481 - 491.

共引文献26

同被引文献42

引证文献5

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部